Business, energy, technology, markets and global industry news from Business News Today

hematology therapeutics

PharmaDeviceNews hematology therapeutics
Pharma & Biotech

Can NovelMed Therapeutics challenge established PNH drugs with its Bb-targeting antibody Ruxoprubart?

NovelMed Therapeutics advances Ruxoprubart for paroxysmal nocturnal hemoglobinuria with Phase II data and a new subcutaneous trial. Discover what comes next.

Read More
Pharma & Biotech

Can Hemab Therapeutics’ sutacimig finally deliver the first preventive therapy for Glanzmann thrombasthenia after FDA breakthrough designation?

FDA grants Breakthrough Therapy Designation to Hemab Therapeutics’ sutacimig for Glanzmann thrombasthenia. Discover what this means for bleeding disorder treatment.

Read More